|Articles|March 24, 2023

California Senate Committee Approves Psychedelics Legalization Bill

California Senate Public Safety Committee approves of SB-58, legalizing the possession and use of specific psychedelics.

In March 2023, a new piece of legislation was approved in the California Senate (1). The bill, SB-58 (2), legalizes possession of certain psychedelics and use of the substances. Senator Scott Wiener (D) refiled the bill back in December 2022, not long after an extensive version was halted in the last session. In its approval hearing, the Senate Public Safety Committee ratified the bill with a 3-1 vote. It will now head on to the Appropriations Committee.

Some of the psychedelics SB-58 legalizes are psilocybin, psilocyn, dimenthyltryptamine (DMT), ibogaine, and mescaline for either facilitated or personal use. Synthetic psychedelics such as lysergic acid diethylamide (LSD) and 3,4-Methyl​enedioxy​methamphetamine (MDMA) which is also known as ecstasy or molly, are not legalized in this bill but were originally included in the previous expansive bill. The new legislation also provides ““group counseling and community-based healing” involving the entheogenic substances (1).

“These are not addictive drugs. And these are drugs that have significant potential in helping people to navigate and to become healthy who are experiencing mental health challenges, substance use challenges,” Wiener mentioned at the approval hearing (1).

“We know that cities in California and elsewhere have passed resolutions to categorize enforcement of these particular criminal laws as the lowest law enforcement priority,” he said. “This is an important step for California. This is about making sure that people have access to substances that they need that are not addictive.”

A separate bill from Assembly member Marie Waldron (R) was introduced in February 2023 (1), with the goal to legalize psychedelics-assisted therapy for military veterans by allowing licensed clinical counselors to administer controlled substances (not limited to psilocybin, LSD, MDMA, ibogaine, and ketamine) to veterans for the treatment of post-traumatic stress disorder (PTSD), traumatic brain injuries, or addiction.

In regards to Wiener’s SB-58 bill, advocates are highly optimistic due to more time to consider the proposal from when it was first introduced and also the growing momentum behind psychedelics.

References

  1. https://www.marijuanamoment.net/california-senators-approve-psychedelics-legalization-bill-in-committee/
  2. https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202320240SB58

Related to this article

2025 Medical Cannabis Roundup
Let’s take a look at the 2025 cannabis coverage on medical cannabis research and medicine to catch up on industry trends and innovations.
Image | adobe.stock/Stock Rocket
Let’s take a look at the 2025 cannabis coverage on cannabis research to catch up on industry trends and innovations.
Manipulating Cannabis Genetics: Pulling Levers to Increase  Phytochemical Composition
Cannabis genetics fundamentally dictate the plant's potential for chemical signatures, including cannabinoid and terpene profiles, and physical traits, such as yield. Cultivators use selective techniques, such as "stacking," to enhance specific compounds. Ultimately, successful cultivation involves balancing superior genetics with environmental "levers" to optimize gene expression and create targeted strains.
Image | adobe.stock/Maksim Kabakou
It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2025. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!